Newswise — With the booming success of GLP-1 drugs, investors are rethinking their approach to funding longevity biotech. The key takeaway? Backing drugs that show measurable effects in a short timeframe is critical to securing long-term investment.
Dr. Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital, explains why the success of GLP-1s underscores the importance of identifying near- and medium-term biomarkers to reduce investment risk in the longevity space.
"The GLP drugs are an incredible class, providing key lessons for investment. A drug that shows measurable effects in a modest time with a modest number of patients can lead to longer studies for confirmation. For healthspan, the key lesson is finding near- to medium-term measurements that de-risk the investment. As investors, we focus on high-risk opportunities and aim to lower that risk, which increases value and reduces capital costs. A super-safe drug with long-term benefits may not be funded, so we need to focus on near-term, disease-oriented solutions that can be expanded."
Would you be interested in learning more about how GLP-1s are shaping investment strategies in longevity biotech?
RSS